Skip to main content
. 2023 Feb 14;14:1111652. doi: 10.3389/fmicb.2023.1111652

Figure 2.

Figure 2

Effect of the probiotic treatment with Ligilactobacillus salivarius CECT 30632 on gout-associated symptomatology and use of hyperuricemic-related drugs during the study in the probiotic group (participants 1 to 15) and in the control group (participants 16–30).